URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)

Core Viewpoint - Monteverde & Associates PC is investigating Titan Pharmaceuticals, Inc. regarding its proposed merger with BSKE Ltd, questioning the fairness of the deal where Titan shareholders would own approximately 13.3% of the combined company [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Merger Details - Titan Pharmaceuticals is set to merge with BSKE Ltd, with a shareholder vote scheduled for August 26, 2025 [1]. - Under the merger agreement, Titan shareholders are expected to hold approximately 13.3% of the new entity [1].